Avalo Therapeutics posts lower-than-expected 2025 net loss

Reuters03-23
Avalo <a href="https://laohu8.com/S/LENZ">Therapeutics</a> posts lower-than-expected 2025 net loss

Overview

  • U.S. IL-1β drug developer's 2025 net loss is lower than expected

  • Operating expenses rose due to increased R&D for Phase 2 LOTUS trial

Outlook

  • Company expects cash and investments at Dec 31, 2025, to fund operations into 2028

Result Drivers

  • R&D SPENDING - Research and development expenses rose $25.6 mln yr/yr due to costs related to and supporting the Phase 2 LOTUS trial

  • G&A EXPENSES - General and administrative expenses increased $5.7 mln yr/yr, primarily due to stock-based compensation and headcount additions

  • WARRANT IMPACT - Net loss widened yr/yr, partly due to a $38.7 mln change in other (expenses) income related to warrants issued in the March 2024 private placement

Company press release: ID:nGNX5NP04m

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

FY Net Income

Beat

-$78.26 mln

-$80.98 mln (9 Analysts)

FY Pretax Profit

Beat

-$78.09 mln

-$80.71 mln (8 Analysts)

FY Operating Expenses

$72.98 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Avalo Therapeutics Inc is $36.00, about 168.3% above its March 20 closing price of $13.42

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment